Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Value of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies.
Tsang M, Bischoff K, Schoenbeck KL, Berry K, O'Riordan D, Fakhri B, Wong SW, Shah N, Olin R, Andreadis C, Vieaux J, Cohen E, Lopez NS, Mannis GN, Rabow M. Tsang M, et al. Among authors: shah n. Blood Adv. 2023 Jul 11;7(13):3146-3149. doi: 10.1182/bloodadvances.2022009039. Blood Adv. 2023. PMID: 36809787 Free PMC article. No abstract available.
Randomized phase 2 study of digital life coaching during transplantation for myeloma.
Banerjee R, Huang CY, Ryan C, Lee A, Brassil KJ, Moore J, Arora S, Chung A, Wong SW, Wolf J, Martin T, Dhruva A, Shah N. Banerjee R, et al. Among authors: shah n. Bone Marrow Transplant. 2023 Dec;58(12):1406-1409. doi: 10.1038/s41409-023-02091-4. Epub 2023 Sep 25. Bone Marrow Transplant. 2023. PMID: 37743374 Clinical Trial. No abstract available.
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy.
Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek SS, Cheung A, Bylsma SA, Hansen E, Wolf JL, Wong SW, Shah N, Roybal KT, Martin TG, Ye CJ, Fong L. Ledergor G, et al. Among authors: shah n. Blood Adv. 2024 Apr 4:bloodadvances.2023012416. doi: 10.1182/bloodadvances.2023012416. Online ahead of print. Blood Adv. 2024. PMID: 38574299
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. Delforge M, et al. Among authors: shah n. Leuk Res. 2023 Jun;129:107074. doi: 10.1016/j.leukres.2023.107074. Epub 2023 Apr 3. Leuk Res. 2023. PMID: 37087950 Free article. Clinical Trial.
8,653 results